Intercure Ltd. Ordinary Shares (INCR) is a publicly traded Healthcare sector company. As of May 21, 2026, INCR trades at $0.84 with a market cap of $44.84M and a P/E ratio of -0.47. INCR moved +0.00% today. Year to date, INCR is -17.79%; over the trailing twelve months it is -46.56%. Its 52-week range spans $0.68 to $2.01. Rallies surfaces INCR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in INCR news today?
InterCure Estimates NIS265M 2025 Revenue, 11% Growth and NIS43M Cash: InterCure estimates full-year 2025 revenue of NIS 265 million, an 11% increase over 2024, with second-half revenue nearly 20% higher than the prior-year period. The company posted its twelfth consecutive positive Adjusted EBITDA, held NIS 43 million in cash at year-end, and generated its first significant revenues from the German market.
Gaenzle Christopher L sold 4.68K (~$255.43K) on Sep 18, 2017.
Rush Gregory S sold 9.70K (~$528.60K) on Sep 18, 2017.
Macdonald Alistair sold 2.35K (~$128.20K) on Sep 18, 2017.
INCR Analyst Consensus
INCR analyst coverage data. Average price target: $0.00.
Common questions about INCR
What changed in INCR news today?
InterCure Estimates NIS265M 2025 Revenue, 11% Growth and NIS43M Cash: InterCure estimates full-year 2025 revenue of NIS 265 million, an 11% increase over 2024, with second-half revenue nearly 20% higher than the prior-year period. The company posted its twelfth consecutive positive Adjusted EBITDA, held NIS 43 million in cash at year-end, and generated its first significant revenues from the German market.
Does Rallies summarize INCR news?
Yes. Rallies summarizes INCR news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is INCR research on Rallies investment advice?
No. Rallies provides research, data, and educational context for INCR. It does not provide personalized investment advice.
